Therefore, we tested if ATRA-refractory AML cell lines with different genetic backgrounds, namely MOLM-13 (FLT3-ITD+) and OCI/AML2 (DNMT3A R635W mutation), would respond to ATRA in combination with EGCG. This evidence concerns the gene FLT3 and acute myeloid leukemia.